Find in Library

<span style="font-size: 12pt; font-family: ">Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy. <span style="color: black;"><span> </span>t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell.<span>  </span>The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective.<span>  </span>Cytogenetic analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is incomplete.<span>  </span></span>Elucidating the genetic pathways and</span><span style="font-size: 12pt; font-family: "> molecular networks that are perturbed in t-MNs, </span><span style="font-size: 12pt; font-family: ">may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies. </span>